Skip to main content

Table 2 Progression-free survival – univariate analysis

From: Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening

   HR 95 % CI p-value
Age   1.0 0.95–1.9 0.12
TN stage T2–3    
  T4 1.9 1.0–3.9 0.06
  N0    
  N1–2 0.97 0.38–2.5 0.95
Baseline CEA ≤ULN    
  >ULN 1.4 0.72–2.8 0.31
ypTN stage ypT0–2    
  ypT3–4 4.2 1.9–9.5 <0.001
  ypN0    
  ypN1–2 3.7 1.8–7.5 <0.001
TRG score TRG1–2    
  TRG3–5 2.4 1.2–4.7 0.01
Post-NACT LCN2 2.2 1.0–4.8 0.05
  MMP9 2.8 1.5–5.9 <0.01
Post-CRT LCN2 2.3 1.0–5.2 0.06
  MMP9 2.9 1.1–3.4 0.03
  1. Adjusted hazard ratio (HR) with 95 % confidence interval (CI); HR above 1: higher probability of unfavorable progression-free survival for the higher value(s) of the parameter. Age and altered serum values (array fluorescence intensities) as fold-change from baseline of lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP9) after induction neoadjuvant chemotherapy (post-NACT) and sequential chemoradiotherapy (post-CRT): entered as continuous data from lowest to highest measurements. CEA carcinoembryonic antigen, ULN upper limit of normal, TRG tumor regression grade